BIOMAT Database Logo BIOMAT Database Logo

Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors. 2019

Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Host Defense Modulation Lab, Collage of Pharmacy, Chung-Ang University, 84 Heukseok-Ro, Dongjak-Gu, Seoul 06974, Republic of Korea; Hanmi Research Center, Hanmi Pharm. Co. Ltd., 550 Dongtangiheung-Ro, Hwaseong-Si, Gyeonggi-Do 18469, Republic of Korea. Electronic address: yykim@hanmi.co.kr.

Colony stimulating factor-1 receptor (CSF-1R or FMS) and it ligand, CSF-1, signaling regulates the differentiation and function of tumor-associated macrophages (TAMs) that play an important role in tumor progression. Derivatives of thieno[3,2-d]pyrimidine were synthesized and evaluated as kinase inhibitors of FMS. The most representative compound 21 showed strong activity (IC50 = 2 nM) against FMS kinase and served as candidate for proof of concept. Anti-tumor activity alone and/or in combination with paclitaxel was examined via a tumor cell growth inhibition assay and via an in vitro tumor invasion assay using human breast adenocarcinoma cells.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors.
May 2024, Bioorganic chemistry,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
February 2020, European journal of medicinal chemistry,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine and quinazoline derivatives as potent antitumor agents.
September 2019, Bioorganic chemistry,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors.
July 2023, Bioorganic chemistry,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis, and biological evaluation of thieno[3,2-d]pyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors.
December 2019, Chemical biology & drug design,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFRL858R/T790M inhibitors.
December 2023, Journal of enzyme inhibition and medicinal chemistry,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents.
November 2014, European journal of medicinal chemistry,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents.
October 2014, European journal of medicinal chemistry,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Synthesis of Thieno[3,2-d]pyrimidine Derivatives through Sequential SN Ar and Suzuki Reactions as Selective h-NTPDase Inhibitors.
July 2023, ChemMedChem,
Yu-Yon Kim, and Jaeyul Choi, and Kyungjin Choi, and Changhee Park, and Young Hoon Kim, and Kwee Hyun Suh, and Young Jin Ham, and Sun Young Jang, and Kyu-Hang Lee, and Kwang Woo Hwang
Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors.
October 2020, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!